Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.

Authors:
Jin Wang
Jin Wang
Center of Medicine Clinical Research
La Mesa | United States
Feng-juan Zhang
Feng-juan Zhang
College of Medicine
China
Na Zhao
Na Zhao
Mayo Clinic
China

Pathol Oncol Res 2019 Jul 25;25(3):1075-1081. Epub 2018 Oct 25.

Department of Interventional Therapy, Henan Provincial People's Hospital, Zhengzhou, China.

To investigate the effect of ultrasound combined with expression of Galectin-3, c-Met, HBME-1 and CK19 in differentiating malignant from benign thyroid nodules. Forty-six patients with thyroid nodules were studied with ultrasound and immunohistochemical staining of excised thyroid nodules. The data were classified and compared. The immunohistochemical staining revealed 8 benign and 41 malignant thyroid lesions. In ultrasound risk assessment, the malignancy risk was low in four nodules, medium in five and high in 37 with lymphatic metastasis in 26. A significant (P < 0.05) association existed in the expression of Galectin-3 with nodule boundary and lymphatic metastasis, in HBME-1 with nodule micro-calcification and in c-Met with nodule micro-calcification and lymphatic metastasis. CK19 expression was not significantly (P > 0.05) associated with any of ultrasound features of nodule. Galectin-3, c-Met, HBME-1 and CK19 were significantly (P < 0.05) different in malignant and benign thyroid lesions, with a significant (P < 0.01) tendency in all the molecular markers in predicting the malignant from benign lesions. The ultrasound characteristics could significantly (P < 0.001) predict malignant nodules with a significant (P < 0.05) prediction tendency. The scores of Galectin-3, c-Met and CK19 significantly (P < 0.05) increased with increase of ultrasound malignancy risk degree. In malignant and benign lesions differentiated by ultrasound, no significant (P > 0.05) difference existed in HBME-1 expression, however, with ultrasound malignancy risk increase, the score of HBME-1 expression increased significantly (P = 0.03). Galectin-3, c-Met, HBME-1 and CK19 have significantly greater expressions in thyroid malignant than benign lesions and their expression increases with increase of ultrasound malignancy risk. The combination of both ultrasound and molecular markers can be used to differentiate malignant and benign thyroid lesions.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-018-0485-6DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2019
2 Reads
1.810 Impact Factor

Publication Analysis

Top Keywords

thyroid nodules
16
c-met hbme-1
12
galectin-3 c-met
12
hbme-1 ck19
12
immunohistochemical staining
8
benign thyroid
8
ultrasound risk
8
malignant benign
8
risk assessment
8
thyroid
5
nodules
5
ultrasound
5
revealed benign
4
malignant thyroid
4
benign malignant
4
classified compared
4
staining excised
4
studied ultrasound
4
nodules studied
4
excised thyroid
4

References

(Supplied by CrossRef)
Article in J Digit Imaging
J Chi et al.
J Digit Imaging 2017
Article in Radiology
JY Kwak et al.
Radiology 2011
Article in Insights Imaging
RK Lingam et al.
Insights Imaging 2013
Article in Ann Surg Oncol
BS Koo et al.
Ann Surg Oncol 2014
Article in J Korean Med Sci
YJ Park et al.
J Korean Med Sci 2007
Article in Ultrasound Q
CC Reading et al.
Ultrasound Q 2005
Article in AJR Am J Roentgenol
EK Kim et al.
AJR Am J Roentgenol 2002
Article in Radiology
WJ Moon et al.
Radiology 2008
Article in Clin Imaging
YJ Hong et al.
Clin Imaging 2010
Article in Eur J Endocrinol
T Rago et al.
Eur J Endocrinol 1998

Similar Publications